Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real-world clinical experience

J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e534-e537. doi: 10.1111/jdv.17997. Epub 2022 Feb 25.

Authors

E Pezzolo^{1

2}, S Cazzaniga^{1

3}, S Di Leo², L Naldi^{1

2}; PsoReal Study Group

Collaborators

Affiliations

¹ Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.
² Department of Dermatology, San Bortolo Hospital, Vicenza, Italy.
³ Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.

PMID: 35143086
DOI: 10.1111/jdv.17997

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Dimethyl Fumarate* / adverse effects
Fumarates / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
Italy
Psoriasis* / drug therapy

Substances

Fumarates
Immunosuppressive Agents
Dimethyl Fumarate

Grants and funding

The study received an unconditioned grant from Alm/Almirall